Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06068179
PHASE2/PHASE3

Graves' Disease Remission Study: MycoMeth Combo

Sponsor: The First Affiliated Hospital of Xiamen University

View on ClinicalTrials.gov

Summary

A randomized study to evaluate the efficacy and safety of combining mycophenolate mofetil with methimazole in patients with newly diagnosed Graves' disease.

Official title: The Efficacy and Safety of Combining Mycophenolate Mofetil With Methimazole on Remission of Newly Diagnosis Graves' Disease (3M-RGD Trial): an Open-label, Randomized Trial

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

205

Start Date

2023-10-16

Completion Date

2026-10-08

Last Updated

2024-02-28

Healthy Volunteers

No

Conditions

Interventions

DRUG

Mycophenolate Mofetil, Oral, 250 Mg

Mycophenolate Mofetil, Oral, 500Mg twice daily for 12 months, combined with methimazole standard therapy

DRUG

methimazole, oral, 10mg

Methimazole 15-30mg daily initially then titrate to maintenance dose.

Locations (1)

Xiao Fangsen

Xiamen, Fujian, China